BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22926105)

  • 1. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
    Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
    Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
    Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
    Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient induction of cytotoxic T lymphocytes in hepatocellular carcinoma using the HLA-A2-restricted survivin peptide in vitro.
    Zhang S; Zeng C; Wang D; Gao X; Guo S; Zhang Y; Shi L
    Exp Cell Res; 2020 Jan; 386(2):111741. PubMed ID: 31759968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
    Li B; Wang Y; Chen J; Wu H; Chen W
    Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
    Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma.
    Dong HL; Li ZS; Ye J; Qu P; Huang YY; Wu W; Lu SY; Chen GS; Sui YF
    Cancer Biol Ther; 2004 Sep; 3(9):891-8. PubMed ID: 15326372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).
    Yoshimura S; Tsunoda T; Osawa R; Harada M; Watanabe T; Hikichi T; Katsuda M; Miyazawa M; Tani M; Iwahashi M; Takeda K; Katagiri T; Nakamura Y; Yamaue H
    PLoS One; 2014; 9(1):e85267. PubMed ID: 24416375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
    Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
    Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
    Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
    Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.
    Jin X; Liu X; Zhou Z; Ding Y; Wu Y; Qiu J; Shen C
    Cancer Immunol Immunother; 2022 Jul; 71(7):1569-1582. PubMed ID: 34724090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].
    Dong HL; Sui YF; Ye J; Li ZS; Qu P; Zhang XM; Chen GS; Lu SY
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1080-3. PubMed ID: 12899783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
    Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
    Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
    Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
    Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
    Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.
    Huang YH; Terabe M; Pendleton CD; Stewart Khursigara D; Bera TK; Pastan I; Berzofsky JA
    PLoS One; 2013; 8(6):e64365. PubMed ID: 23750208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
    Tomimaru Y; Mishra S; Safran H; Charpentier KP; Martin W; De Groot AS; Gregory SH; Wands JR
    Vaccine; 2015 Mar; 33(10):1256-66. PubMed ID: 25629522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.